Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 86.88M-74.8% |
| Revenue (ttm) | 0 |
| Net Income | -212.75M+15.6% |
| EPS | -1.23+21.7% |
| Shares Out | 185.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290,204.73 |
| Open | 0.46 |
| Previous Close | 0.47 |
| Day's Range | 0.46 - 0.48 |
| 52-Week Range | 0.45 - 3.65 |
| Beta | 2.97 |
| Analysts | Buy |
| Price Target | 4.50(+859.69%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NMRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NMRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NMRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NMRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NMRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NMRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NMRA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $4.57M |
| VXFVanguard Extended Market ETF | $1.50M |
| IWMiShares Russell 2000 ETF | $1.20M |
| VTWOVanguard Russell 2000 ETF | $784.15K |
| IWOiShares Russell 2000 Growth ETF | $501.59K |
| IBBiShares Biotechnology ETF | $274.24K |
Estimated from each fund’s disclosed top holdings × AUM
NMRA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NMRA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score